The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...

3M's end markets remain mixed, but management has a margin expansion opportunity. CEO Bill Brown will outline his vision for the company in February. The stock looks like a good value and is a ...

3M returned $1.1 billion to shareholders via dividends and share repurchases. Cash from operations of $1.8 billion. Adjusted free cash flow of $1.3 billion.

Gains in areas like industrial adhesives, electronics ... improve and consolidate its mammoth supply chain (3M has 25,000 suppliers with 80% of its raw materials coming from single sources ...

As of now, 3M offers an annual dividend yield of 2.01%, which is a quarterly dividend amount of 70 cents per share ($2.80 a year). So, how can investors exploit its dividend yield to pocket a ...